Assessment of viral loads in patients with chronic hepatitis C with AMPLICOR HCV MONITOR version 1.0, COBAS HCV MONITOR version 2.0, and QUANTIPLEX HCV RNA version 2.0 assays

Journal of Clinical Microbiology

Volumn 38, Issue 7, 2000, Pages 2722-2725

  Martinot Peignoux, Michéle ^a   Le Breton, Véronique ^a   Fritsch, Sandrine ^b   Le Guludec, Gaëlle ^a   Labouret, Nathalie ^b   Keller, Françoise ^b   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; VIRUS DIAGNOSIS; VIRUS LOAD;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0033943691     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.38.7.2722-2725.2000     Document Type: Article

References (23)

1. Afonso, A. M., J. Didier, E. Plouvier, B. Falissard, M .P. Ferey, M. Bogard, and E. Dussaix. 2000. Performance of an automated system for quantification of hepatitis C virus RNA. J. Virol. Methods 86:55-60.
2. Albadalejo, J., R. Alonzo, R. Antinozzi, M. Bogard, A. M. Bourgault, G. Colucci, T. Fenner, H. Petersen, E. Sala, J. Vincelette, and C. Young. 1998. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for detection of hepatitis C virus RNA in the diagnostic laboratory. J. Clin. Microbiol. 36:862-865.
3. Davis, G., and J. Lau. 1997. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 20(Suppl.):S123-S127.
4. Davis, G. L., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M. H. Ling, and J. Albrecht. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New Engl. J. Med. 339:1493-1499.
5. Detmer, J., R. Lagier, J. Flynn, C. Zayat, J. Kolberg, M. Collins, M. Urdea, and R. Sanchez-Pescador. 1996. Accurate quantification of hepatitis C virus (HCV) RNA from all genotypes by using branched-DNA technology. J. Clin. Microbiol. 34:901-907.
6. Doglio, A., C. Laffont, F. X. Caroli-Bosc, P. Rochet, and J. C. Lefebvre. 1999. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J. Clin. Microbiol. 37:1567-1569.
7. EASL International Consensus Conference on Hepatitis C. 1999. Consensus statement. J. Hepatol. 30:956-961.
8. Gretch, D. R., C. De la Rosa, R. L. Carithers, Jr., R. A. Willson, B. Williams, and L. Corey. 1995. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann. Intern. Med. 123:321-329.
9. Hawkins, A., F. Davidson, and P. Simmonds. 1997. Comparison of plasma virus load among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Quantiplex HCV RNA assay version 1 and 2, Roche Monitor assay, and an in-house limiting dilution method. J. Clin. Microbiol. 35:187-192.
10. Kolberg, J. A., R. Sanchez-Pescador, J. Detmer, M. Collins, P. Sheridan, P. Neuwald, J. Wilber, et al. 1994. Branched DNA quantitation of hepatitis C viral RNA in patient sera, p. 57-70. In Groupe Français d'Études Moléculaires des hépatites virales (GEMHEP) (ed.), Hepatitis C virus: new diagnostic tools. John Libbey Eurotext, Paris, France.
11. Lau, J. Y. N., P. Simmonds, and M. Urdea. 1995. Implication of variations of "conserved" regions of hepatitis C virus genome. Lancet 346:425-426.
12. Lau, J. Y. N., G. L. Davis, L. E. Prescott, G. Maertens, K. L. Lindsay, K. P. Quian, M. Mizokami, P. Simmonds, and the Hepatitis Interventional Therapy Group. 1996. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in United States. Ann. Intern. Med. 124:868-876.
13. Lunel, F., P. Cresta, D. Vitour, C. Payan, B. Dumont, L. Frangeul, D. Reboul, C. Brault, J. C. Piette, and J. M. Huraux. 1999. Comparative evaluation of hepatitis C virus RNA quantitation by bDNA, NASBA, and Monitor assays. Hepatology 29:528-535.
14. Martinot-Peignoux, M., P. Marcellin, M. Pouteau, C. Castelnau, N. Boyer, M. Poliquen, C. Degott, V. Descombes, V. Lebreton, V. Milotova, J. D. Benhamou, and S. Erlinger. 1995. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 22:1050-1056.
15. Martinot-Peignoux, M., N. Boyer, M. Pouteau, C. Castelnau, N. Giuily, V. Duchatelle, A. Aupérin, C. Degott, J. P. Benhamou, S. Erlinger, and P. Marcellin. 1998. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J. Hepatol. 29:214-223.
16. Martinot-Peignoux, M., F. Roudot-Thoraval, I. Mendel, J. Coste, J. Izopet, G. Duverlie, C. Payan, J. M. Pawlotsky, C. Defer, M. Bogard, V. Gerolami, P. Halfon, Y. Buisson, B. Fouqueray, P. Loiseau, J. Lamoril, J. J. Lefrère, P. Marcellin, and the GEMHEP. 1999. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. J. Viral Hepatol. 6:435-443.
17. McHutchinson, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. Goodman, M. H. Ling, S. Cort, and J. Albrecht. 1999. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl. J. Med. 339:1485-1492.
18. Mellor, J., A. Hawkins, and P. Simmonds. 1999. Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. J. Clin. Microbiol. 37:2525-2532.
19. Pawlotsky, J. M., I. Lonjon, C. Hézode, B. Raynard, F. Darthuy, J. Rémiré, C. J. Soussy, and D. Dhumeaux. 1998. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 27:1700-1702.
20. Pawlotsky, J. M., M. Martinot-Peignoux, J. D. Poveda, A. Bastie, V. Le Breton, F. Darthuy, J. Remeri, S. Erlinger, D. Dhumeaux, and P. Marcellin. 1999. Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays. J. Virol. Methods 79:227-235.
21. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, and J. Albrecht. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
22. Roth, W. K., J. H. Lee, B. Ruster, and S. Zeuzem. 1996. Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays. J. Clin. Microbiol. 34:261-264.
23. Stuyver, L., R. Rossau, A. Wyseur, M. Duhamel, B. Vanderborght, H. Van Heuverswyn, and G. Maertens. 1993. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J. Gen. Virol. 74:1093-1102.